Modelling a Silent Epidemic: A Review of the In Vitro Models of Latent Tuberculosis
Open Access
- 15 November 2018
- Vol. 7 (4), 88
- https://doi.org/10.3390/pathogens7040088
Abstract
Tuberculosis (TB) is the primary cause of death by a single infectious agent; responsible for around two million deaths in 2016. A major virulence factor of TB is the ability to enter a latent or Non-Replicating Persistent (NRP) state which is presumed untreatable. Approximately 1.7 billion people are latently infected with TB and on reactivation many of these infections are drug resistant. As the current treatment is ineffective and diagnosis remains poor, millions of people have the potential to reactivate into active TB disease. The immune system seeks to control the TB infection by containing the bacteria in a granuloma, where it is exposed to stressful anaerobic and nutrient deprived conditions. It is thought to be these environmental conditions that trigger the NRP state. A number of in vitro models have been developed that mimic conditions within the granuloma to a lesser or greater extent. These different models have all been utilised for the research of different characteristics of NRP Mycobacterium tuberculosis, however their disparity in approach and physiological relevance often results in inconsistencies and a lack of consensus between studies. This review provides a summation of the different NRP models and a critical analysis of their respective advantages and disadvantages relating to their physiological relevance.Other Versions
Funding Information
- Academy of Medical Sciences (SBF003\1088)
This publication has 88 references indexed in Scilit:
- Modeling the Mycobacterium tuberculosis Granuloma – the Critical Battlefield in Host Immunity and DiseaseFrontiers in Immunology, 2013
- Cholesterol Catabolism by Mycobacterium tuberculosis Requires Transcriptional and Metabolic AdaptationsCell Chemical Biology, 2012
- Profiling Early Lung Immune Responses in the Mouse Model of TuberculosisPLOS ONE, 2011
- Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2010
- Mycobacterium tuberculosis Is Able To Accumulate and Utilize CholesterolJournal of Bacteriology, 2009
- Metronidazole Lacks Antibacterial Activity in Guinea Pigs Infected with Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2008
- Metronidazole Lacks Activity againstMycobacterium tuberculosisin an In Vivo Hypoxic Granuloma Model of LatencyThe Journal of Infectious Diseases, 2008
- Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicalsMethods, 2007
- Identification of gene targets against dormant phase Mycobacterium tuberculosis infectionsBMC Infectious Diseases, 2007
- Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2007